Healthy Volunteers Clinical Trial
Official title:
PET Imaging of Nicotinic Acetylcholine Receptors With 2-[18F]F-A-85380-Injection, Initial Evaluation of Radiotracer in Human Volunteers
Background:
- Central nicotinic acetylcholine receptors (nAChRs) are the primary target for the action of
nicotine. In addition to being involved in tobacco dependence, they are also involved in a
variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are
interested in developing better ways to study the action of nAChRs to improve treatments for
smoking cessation and other problems affected by these receptors. These new study methods may
involve different radiotracers, which are drugs that can help show brain activity during
positron emission tomography (PET) scanning.
Objectives:
- To evaluate the feasibility of using a radiotracer, 2-[18F]F-A-85380, in PET scanning of
the brain.
Eligibility:
- Healthy volunteers between 21 and 45 years of age who do not use tobacco.
Design:
- Participants will be asked to avoid consuming alcohol or using a number of
over-the-counter medications, including antihistamines, cough medicines, and nasal
decongestants, for 5 days before the study day. Participants provide urine and breath
samples at the start of the study to be tested for chemicals that may interfere with the
study.
- Participants will visit the clinical center the morning of the day before the scanning
session to provide blood and urine samples as required. Participants will return and be
admitted for an overnight stay later that afternoon or evening.
- On the day of the study, participants will receive a single dose of the radiotracer
2-[18F]F-A-85380, and will have a series of PET scans over the next 7 hours and provide
blood samples during that time. Participants will spend that night at the clinical
center and leave on the morning after the end of the study.
- Participants will return for follow-up visits 2 weeks and 1 month after the end of the
study.
Background: Central nicotinic acetylcholine receptors (nAChRs) mediate a variety of brain
functions and have been implicated in the pathophysiology of Alzheimer's and Parkinson's
diseases, other CNS disorders (Tourette's syndrome, epilepsy, etc.), and nicotine dependence.
These receptors are the primary target for the action of nicotine, which is believed to cause
tobacco dependence. The availability of a suitable agent that could image nAChRs with PET in
humans would allow scientists to monitor the nAChRs in vivo for the purpose of determining
their roles in the pathogenesis of neurodegenerative diseases and nicotine dependence.
Scientific Goals: The immediate goal of the proposed study is to evaluate the feasibility of
using a radiotracer, 2-[18F]F-A-85380, developed by scientists in the NIDA Brain Imaging
Center for external imaging of nAChRs in the human brain.
Study Population: Healthy adult participants, males and females between 21 and 45 years of
age, will be recruited for this study. The goal is to complete studies of 7 male and 7 female
subjects.
Experimental Design and Method: After being medically cleared and giving informed consent,
participants will receive a single dose of the radiotracer, 2 [18F]F A 85380-Injection, and
will undergo a series of PET scans acquired over the next 7 hours after the injection. The
PET scans will be used to determine the time course of the distribution of the injected
radioactivity in those organs expected to receive the highest radiation exposure and in the
brain.
Benefits to participants and/or society: This protocol will provide no direct benefits to the
research participants other than routine medical screening and attention from the research
staff. The knowledge gained in this study may lead to the availability of an agent for
external monitoring of nAChRs using PET. This agent would be a valuable tool for determining
the role of nAChRs in the pathogenesis of neuropsychiatric diseases, including nicotine
dependence and for developing medications for diseases that respond to nicotinic agonists.
Risks to participants: There is some risk attendant to the PET scans in general, involving
exposure to radiation, arterial catheterization and venous catheterization. In addition,
there is risk related to the administration of this radiopharmaceutical, as it will be given
to humans for the first time in this study. Medical supervision will be provided throughout
the study. A plan for monitoring potential side effects of this radiotracer is given.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |